Lundbeck has entered into a definitive agreement with AprilBio, a biopharmaceutical company based in South Korea. Under the agreement between the two companies, Lundbeck receives exclusive, worldwide rights to research, develop and commercialize APB-A1, a novel and well-differentiated anti-CD40 lAlready a subscriber Login You have read all your free articles,…